X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1139) 1139
Book Review (77) 77
Publication (73) 73
Conference Proceeding (71) 71
Book Chapter (13) 13
Patent (6) 6
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (431) 431
humans (404) 404
gastroenterology & hepatology (400) 400
gastroenterology and hepatology (288) 288
female (246) 246
male (243) 243
adult (215) 215
crohn's disease (193) 193
inflammatory bowel disease (191) 191
ulcerative colitis (167) 167
inflammatory-bowel-disease (164) 164
middle aged (163) 163
infliximab (158) 158
crohns-disease (149) 149
abridged index medicus (111) 111
ulcerative-colitis (108) 108
crohn disease - drug therapy (99) 99
treatment outcome (99) 99
young adult (82) 82
adolescent (81) 81
inflammatory bowel diseases (78) 78
aged (72) 72
care and treatment (72) 72
risk factors (72) 72
crohn disease - genetics (71) 71
colitis, ulcerative - drug therapy (67) 67
therapy (67) 67
antibodies, monoclonal - therapeutic use (66) 66
case-control studies (62) 62
genetic predisposition to disease (59) 59
analysis (52) 52
tumor necrosis factor-alpha - antagonists & inhibitors (52) 52
antibodies (51) 51
crohns disease (51) 51
gastrointestinal agents - therapeutic use (50) 50
inflammatory bowel diseases - drug therapy (49) 49
genetic aspects (48) 48
research (48) 48
genotype (47) 47
medical research (47) 47
maintenance therapy (46) 46
adalimumab (44) 44
genetics (43) 43
retrospective studies (43) 43
ibd (42) 42
cohort studies (40) 40
crohn disease - immunology (40) 40
follow-up studies (40) 40
inflammation (40) 40
pharmacology & pharmacy (40) 40
gastrointestinal diseases (39) 39
association (37) 37
efficacy (37) 37
inflammatory bowel diseases - genetics (37) 37
remission (37) 37
colitis, ulcerative - genetics (36) 36
rheumatoid-arthritis (36) 36
polymorphism, single nucleotide (35) 35
prospective studies (35) 35
clinical trials (34) 34
crohn disease - diagnosis (34) 34
genome-wide association (34) 34
patients (34) 34
risk (34) 34
anti-inflammatory agents - therapeutic use (33) 33
intestine (33) 33
medicine, experimental (33) 33
prognosis (33) 33
severity of illness index (33) 33
colitis (31) 31
diagnosis (31) 31
gastroenterology (31) 31
remission induction (31) 31
inflammatory bowel diseases - immunology (30) 30
susceptibility (30) 30
animals (29) 29
biopsy (29) 29
child (29) 29
monoclonal antibodies (29) 29
phenotype (29) 29
studies (29) 29
azathioprine (28) 28
belgium (28) 28
c-reactive protein (28) 28
crohn disease - pathology (28) 28
genome-wide association study (27) 27
immunogenicity (27) 27
susceptibility loci (27) 27
tumor necrosis factor (27) 27
colitis, ulcerative - pathology (26) 26
crohn’s disease (26) 26
double-blind (26) 26
genes (26) 26
genetics & heredity (26) 26
induction (26) 26
safety (26) 26
aged, 80 and over (25) 25
colitis, ulcerative - immunology (25) 25
expression (25) 25
gene expression (25) 25
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Romagnoni, A and Jegou, S and Van Steen, K and Wainrib, G and Hugot, JP and Peyrin-Biroulet, L and Chamaillard, M and Colombel, JF and Cottone, M and D'Amato, M and D'Inca, R and Halfvarson, J and Henderson, P and Karban, A and Kennedy, NA and Khan, MA and Lemann, M and Levine, A and Massey, D and Milla, M and Ng, SME and Oikonomou, I and Peeters, H and Proctor, DD and Rahier, JF and Rutgeerts, P and Seibold, F and Stronati, L and Taylor, KM and Torkvist, L and Ublick, K and Van Limbergen, J and Van Gossum, A and Vatn, MH and Zhang, H and Zhang, W and Andrews, JM and Bampton, PA and Barclay, M and Florin, TH and Gearry, R and Krishnaprasad, K and Lawrance, IC and Mahy, G and Montgomery, GW and Radford-Smith, G and Roberts, RL and Simms, LA and Hanigan, K and Croft, A and Amininijad, L and Cleynen, I and Dewit, O and Franchimont, D and Georges, M and Laukens, D and Theatre, E and Vermeire, S and Aumais, G and Baidoo, L and Barrie, AM and Beck, K and Bernard, EJ and Binion, DG and Bitton, A and Brant, SR and Cho, JH and Cohen, A and Croitoru, K and Daly, MJ and Datta, LW and Deslandres, C and Duerr, RH and Dutridge, D and Ferguson, J and Fultz, J and Goyette, P and Greenberg, GR and Haritunians, T and Jobin, G and Katz, S and Lahaie, RG and McGovern, DP and Nelson, L and Ng, SM and Ning, K and Pare, P and Regueiro, MD and Rioux, JD and Ruggiero, E and Schumm, LP and Schwartz, M and Scott, R and Sharma, Y and Silverberg, MS and Spears, D and Steinhart, AH and Stempak, JM and Swoger, JM and Tsagarelis, C and ... and Int Inflammatory Bowel Dis Genetic and International Inflammatory Bowel Disease Genetics Consortium (IIBDGC)
SCIENTIFIC REPORTS, ISSN 2045-2322, 07/2019, Volume 9, Issue 1, pp. 1 - 18
Crohn Disease (CD) is a complex genetic disorder for which more than 140 genes have been identified using genome wide association studies (GWAS). However, the... 
LOCI | INFLAMMATORY-BOWEL-DISEASE | RISK PREDICTION | ASSOCIATION | MULTIDISCIPLINARY SCIENCES | Inflammatory bowel diseases | Complementarity | Epistasis | Genomes | Genetic variance | Learning algorithms | Genetic markers | Genotyping | Intestine | Neural networks | Machine learning | Quality control | Artificial intelligence | Genotypes
Journal Article
Gastroenterology, 08/2019
BACKGROUND & AIMSMaintenance treatment with vedolizumab, a monoclonal antibody that inhibits the gut-selective α4β7 integrin, is administered intravenously.... 
Index Medicus | Abridged Index Medicus
Journal Article
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 08/2019
BACKGROUND & AIMSWe aimed to identify biomarkers that might be used to predict responses of patients with inflammatory bowel diseases (IBD) to vedolizumab... 
Index Medicus
Journal Article
Inflammatory Bowel Diseases, ISSN 1078-0998, 08/2019
BACKGROUNDUnlike other anti-tumor necrosis factor alpha antibodies, golimumab does not deliver on its promise of effectiveness for treating patients with... 
Index Medicus
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 08/2019, Volume 17, Issue 9, pp. 1673 - 1679.e1
In 2016, the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) released revised EMA and new FDA draft guidelines related to the... 
EMA | FDA | Inflammatory Bowel Disease | Drug Development | Ulcerative Colitis | Guidelines | END-POINTS | GASTROENTEROLOGY & HEPATOLOGY | Drugs | Comparative analysis | Drug therapy | Ulcerative colitis | Index Medicus
Journal Article
Journal of Crohn's and Colitis, ISSN 1873-9946, 07/2019, Volume 13, Issue 7, pp. 916 - 930
Journal Article
Journal of Crohn's & colitis, 01/2019, Volume 13, Issue 7, pp. 864 - 872
Ustekinumab, an anti-IL12/23p40 monoclonal antibody, has been approved for Crohn's disease (CD). Real-life data in CD patients receiving ustekinumab... 
Index Medicus
Journal Article
Journal of Crohn's & colitis, 01/2019, Volume 13, Issue 7, pp. 916 - 930
Early treatment of Crohn's disease (CD) is required to optimize patient outcomes. To this end, we need to gain a better understanding of the molecular changes... 
Index Medicus
Journal Article
Journal of Crohn's and Colitis, ISSN 1873-9946, 07/2019, Volume 13, Issue 7, pp. 864 - 872
Journal Article
Gastroenterology, 07/2019
BACKGROUND & AIMSVedolizumab is a gut-selective monoclonal antibody for the treatment of moderately to severely active Crohn's disease (CD). We performed a... 
Index Medicus | Abridged Index Medicus
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 07/2019, Volume 17, Issue 8, pp. 1643 - 1645
The postoperative endoscopic recurrence score, commonly referred to as the Rutgeerts score, was designed to predict clinical recurrence risk in Crohn's disease... 
GASTROENTEROLOGY & HEPATOLOGY | IMPACT | POSTOPERATIVE RECURRENCE
Journal Article
United European Gastroenterology Journal, ISSN 2050-6406, 7/2019, Volume 7, Issue 6, pp. 750 - 758
Background Very little is known about the impact of the wash-out period on the pharmacokinetics of a second-line biologic. Objective The objective of this... 
vedolizumab | Induction | wash-out | infliximab | pharmacokinetics | trough level | inflammatory bowel disease | RHEUMATOID-ARTHRITIS | ANTIBODIES | SAFETY | COMBINATION THERAPY | PHARMACODYNAMICS | MAINTENANCE THERAPY | GASTROENTEROLOGY & HEPATOLOGY | Original
Journal Article
Clinical Gastroenterology and Hepatology, ISSN 1542-3565, 07/2019, Volume 17, Issue 8, pp. 1643 - 1645
The postoperative endoscopic recurrence score, commonly referred to as the Rutgeerts score, was designed to predict clinical recurrence risk in Crohn's disease... 
Journal Article
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 07/2019, Volume 34, Issue 7, pp. 1175 - 1181
Background and Aim The pivotal GEMINI trials reported low immunogenicity of vedolizumab. However, anti-vedolizumab antibodies (AVA) are frequently... 
vedolizumab | treatment discontinuation | immunogenicity | inflammatory bowel disease | ANTIBODIES | INDUCTION THERAPY | OUTCOMES | INFLIXIMAB | GASTROENTEROLOGY & HEPATOLOGY | MAINTENANCE THERAPY | PREGNANCY | Viral antibodies | Antibodies | Care and treatment | Biological products | Drug resistance | Gastrointestinal diseases
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.